W B SAUNDERS CO LTD

• 

  Publisher Of

  • Determinants of matrix metalloproteinases plasma concentration and activity in premature coronary atherosclerosis.  European Heart Journal.  23:135-135. 2002
  • Effect of simvastatin on endothelial damage markers and clinical outcomes in acute coronary syndromes.  European Heart Journal.  23:419-419. 2002
  • Baseline characteristics that identify patients at high risk of death following myocardial infarction. Preliminary findings from the ALIVE trial.  European Heart Journal.  22:700-700. 2001
  • Body mass index remains a significant predictor of outcome after percutaneous coronary interventions in the era of IIbIIIa inhibition.  European Heart Journal.  22:524-524. 2001
  • Eptifibatide (Integrilin (R)) in coronary stent implantation: long-term results of the ESPRIT trial.  European Heart Journal.  22:121-121. 2001
  • Genetic variation in human Stromelysin-1 and Gelatinase B genes and acute coronary syndromes in young males.  European Heart Journal.  22:164-164. 2001
  • Increased rates of stent thrombosis among patients with acute coronary syndromes: insights from two large oral IIb/IIIa antagonist trials.  European Heart Journal.  22:385-385. 2001
  • Low heart rate variability (triangular index method) predicts mortality independent of beta-blocker usage, LVEF, and other factors: ALIVE trial early findings.  European Heart Journal.  22:701-701. 2001
  • Pharmacokinetic and pharmacodynamic responses of the novel factor Xa inhibitor DX-9065a: results from the Xa neutralization for atherosclerotic disease understanding (XaNADU) IB trial.  European Heart Journal.  22:664-+. 2001
  • The ALIVE study: heart rate variability prospectively identifies patients at high risk of death after myocardial infarction.  European Heart Journal.  22:696-+. 2001
  • Educational level and 30-day mortality after acute myocardial infarction: results from the GUSTO III trial.  European Heart Journal.  21:223-223. 2000
  • Social isolation and 30-day mortality after acute myocardial infarction: results from the GUSTO III trial.  European Heart Journal.  21:213-213. 2000
  • The level of platelet inhibition maintained with a GPIIb/IIIa inhibitor following coronary intervention is strongly associated with the risk of a post-procedural MACE: results of the GOLD study.  European Heart Journal.  21:145-145. 2000
  • Use of a near-patient, whole blood, multi-marker strategy (MMS) for evaluation of patients with chest pain: Results of the CHECKMATE study.  European Heart Journal.  21:19-19. 2000
  • INTRAARTICULAR IL1-RA AFTER ACUTE KNEE INJURY DECREASES BIOMARKERS OF INFLAMMATION AND IMPROVES PAIN AND FUNCTION.  Osteoarthritis and Cartilage. S11-S12. 2010
  • "Leading and lagging" hospitals: can processes of care be used to rank hospitals?.  European Heart Journal. 444-444. 2004
  • Continuous ST-segment recovery analysis is significantly more predictive of mortality than serial static analysis after thrombolytic therapy for acute MI.  European Heart Journal. 299-299. 2004
  • Low haemoglobin is associated with more evidence of congestion but less severe systolic dysfunction in patients with chronic heart failure.  European Heart Journal. 498-498. 2004
  • Substantial reduction in all-cause mortality and morbidity with candesartan in patients with chronic heart failure and systolic left ventricular dysfunction: results of the CHARM low EF trials.  European Heart Journal. 487-487. 2004
  • Altered levels of serum cartilage markers in postmenopausal African-American and caucasian women on current hormone replacement therapy.  Osteoarthritis and Cartilage. S54-S55. 2004
  • Improved precision of quantitative cartilage measurements with magnetic resonance imaging at 3 T.  Osteoarthritis and Cartilage. S119-S119. 2004
  • Using epidemiologic studies to identify surrogates for radiographic outcome.  Osteoarthritis and Cartilage. S9-S9. 2004
  • Cost-effectiveness of valsartan in patients not receiving angiotensin-converting enzyme inhibitors at baseline.  European Heart Journal. 137-137. 2002
  • Effect of tenecteplase versus alteplase on platelets in patients during the first three hours after acute myocardial infarction.  European Heart Journal. 267-267. 2002
  • How does ST-segment resolution one-hour after fibrinolysis for acute myocardial infarction predict final infarct size? Insights from ASSENT 3.  European Heart Journal. 266-266. 2002
  • Predictors of in-hospital mortality in the global registry of acute coronary events (GRACE).  European Heart Journal. 626-626. 2002
  • TNK with reduced dose unfractionated heparin associated with similar efficacy and less bleeding: results from ASSENT-2 and ASSENT-3.  European Heart Journal. 638-638. 2002
  • Conivaptan (CI-1025, YM087), a combined vasopressin V1A/V2 antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum Na or vasopressin levels in heart failure.  European Heart Journal. 541-541. 2001